A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation

Henrik Frithiof, Kristina Aaltonen, Lisa Rydén

Research output: Contribution to journalArticlepeer-review

15 Citations (SciVal)

Abstract

Amplification of the HER-2/neu (HER-2) proto-oncogene occurs in 10%–15% of primary breast cancer, leading to an activated HER-2 receptor, augmenting growth of cancer cells. Tumor classification is determined in primary tumor tissue and metastatic biopsies. However, malignant cells tend to alter their phenotype during disease progression. Circulating tumor cell (CTC) analysis may serve as an alternative to repeated biopsies. The Food and Drug Administration-approved CellSearch system allows determination of the HER-2 protein, but not of the HER-2 gene. The aim of this study was to optimize a fluorescence in situ hybridization (FISH)-based method to quantitatively determine HER-2 amplification in breast cancer CTCs following CellSearch-based isolation and verify the method in patient samples.
Original languageEnglish
Pages (from-to)7095-7103
JournalOncoTargets and Therapy
Volume2016
Issue number9
DOIs
Publication statusPublished - 2016

Subject classification (UKÄ)

  • Cancer and Oncology

Fingerprint

Dive into the research topics of 'A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation'. Together they form a unique fingerprint.

Cite this